Latest 5 articles from heartwire
- Air pollutants mediate effects on heart health through inflammation and thrombosis
May 17, 2012 17:15 EDT - Statins benefit those at much lower CV risk
May 16, 2012 18:30 EDT - Azithromycin may up chance of sudden cardiac death
May 16, 2012 17:00 EDT - So long, Plavix, what a ride! Clopidogrel patent expires
May 16, 2012 14:45 EDT - COMFORTABLE-AMI: Bioerodable polymer DES trumps bare metal in STEMI
May 16, 2012 10:50 EDT
ARBITER 6-HALTS: What are the clinical implications?
Posted Nov 18, 2009
at 12:45 PM, EDT
by Seth Bilazarian
In this trial extended-release niacin was shown to be superior to ezetimibe with a surrogate endpoint of carotid IMT. As we wait for more complete data from the AIM-HIGH and IMPROVE-IT trials, how will the results of ARBITER 6-HALTS affect your daily practice? Will you use potent statins more and zetia less while we wait until 2012 for the IMPROVE-IT study?
See:
ARBITER 6-HALTS: HDL raising with niacin superior to ezetimibe
Ezetimibe in ARBITER 6-HALTS: What lessons can we learn?
ARBITER 6-HALTS: Will you refill or newly prescribe ezetimibe/Zetia after today?
Previous posts
Choosing wisely for interventionalists: Seth Bilazarian's top 5
1 Comments |
Posted May 10, 2012
at 03:15 AM, EDT by Seth
at 03:15 AM, EDT by Seth
The Choosing Wisely initiative: The ACC and ASNC list what NOT to do
No comments |
Posted May 02, 2012
at 10:25 AM, EDT by Seth
at 10:25 AM, EDT by Seth
Left ventriculography: Setting the record straight
2 Comments |
Posted Apr 11, 2012
at 03:35 AM, EDT by Seth
at 03:35 AM, EDT by Seth
Facebook, LinkedIn, and YouTube: What place in the cardiology practice?
No comments |
Posted Apr 04, 2012
at 04:00 PM, EDT by Seth
at 04:00 PM, EDT by Seth
Renal-nerve denervation to combat resistant hypertension
5 Comments |
Posted Mar 26, 2012
at 05:25 PM, EDT by Seth
at 05:25 PM, EDT by Seth
Also from theheart.org
About Dr Seth Bilazarian
Seth Bilazarian MD has been a Clinical and Interventional Cardiologist at Pentucket Medical Associates in Massachusetts since 1993. He is board certified in Internal Medicine, Cardiovascular Medicine, Nuclear Cardiology, Vascular Ultrasound, Interventional Cardiology, and Vascular and Endovascular Medicine.
Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.
Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.
Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
About this blog
My intent is to create a forum for dialogue on issues pertinent to private practice cardiology around topics such as:
- Integration of new data and guidelines on inpatient and outpatient practice in clinical and interventional cardiology
- Practice approaches to the extra clinical issues in dealing with managed care insurers
- Strategies for navigating the restrictions of pharmacy benefits managers (PBMs) on pharmacologic therapies for our patients
- Experiences with restrictions on testing and imaging














Comments
The track record of excellent correlation between carotid IMT and coronary IVUS responses in clinical trials is to me a strong support of the validity of Arbiter-6 Halts conclusions. I will expect an IVUS study of the same meds as Arbiter used to show similar results.